Type A Aortic Dissection With Residual Type B DissectionADEPTNCT07315178
Creation of a Digital Twin for Predicting the Progression of Patients With Chronic Thoracic Aortic Dissection
A study testing MRI with 4D flow imaging and blood sampling in people with Type A Aortic Dissection With Residual Type B Dissection and Chronic Type B Aortic Dissection, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
Aortic dissection causes a tear in the inner layers of the aorta, leading to the formation of a true and false lumen. There are two types of dissection: type A, which affects the ascending aorta, and type B, which affects the descending aorta. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type A Aortic Dissection With Residual Type B Dissection, Chronic Type B Aortic Dissection
- What is being tested?
- MRI with 4D flow imaging and blood sampling
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteFrance
- Study dates
- 25 Nov 2025to Nov 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Person who has given written consent
- Age > 18 years
- Patient with type A aortic dissection with surgical indication for replacement
- Patient with chronic type B aortic dissection, monitored and managed medically, not operated on
Who cannot join
- Persons not affiliated with or not covered by a social security scheme
- Persons subject to legal protection measures (guardianship)
- Persons subject to judicial protection measures
- Pregnant women, women in labour or breastfeeding
- Adults who are incapacitated or unable to give their consent
- Contraindications to MRI: claustrophobia, non-MRI-compatible metal implants, suspected metal foreign body
Show all 11Show fewer
- Severe renal failure (clearance <30ml/min according to Cockroft due to gadolinium injection)
- Uncontrolled asthma
- Patients with acute type A aortic dissection who died during or in the post-operative period following surgery to repair the dissection
- Patients with a known allergy to gadolinium-based contrast agents
- Patients treated for type B aortic dissection who underwent surgery
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Alain Lalande contact
France1 site, 1 recruiting
- Recruiting
Chu Dijon Bourgogne
Dijon, 21000
Alain Lalande, alain.lalande@u-bourgogne.fr
About this study
Aortic dissection causes a tear in the inner layers of the aorta, leading to the formation of a true and false lumen.
There are two types of dissection: type A, which affects the ascending aorta, and type B, which affects the descending aorta. Type A aortic dissection is almost always a surgical emergency and involves replacing the ascending aorta with a prosthesis. After this type of dissection, a residual dissection remains in the descending aorta, known as residual type B dissection, which becomes chronic. This requires increased monitoring by MRI or CT scan, which are currently not effective enough to predict the development of an aneurysm that could lead to aortic rupture requiring surgical intervention. Other factors such as blood flow, the forces and mechanisms regulating blood circulation, the mechanics and histology of the aorta, and blood markers could provide a more reliable prediction of the development of an aneurysm. The creation of a digital twin model incorporating all these factors should enable better patient management.
- Conditions
- Type A Aortic Dissection With Residual Type B Dissection, Chronic Type B Aortic Dissection
- Being tested
- MRI with 4D flow imaging, blood sampling
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRI with 4D flow imagingOther
At 3 months
blood samplingBiological
2 tubes of 10 ml blood at inclusion, at 3 months, at 12 months, at 24 months and at 36 months
| Study group | Role | What they receive |
|---|---|---|
| Type B aortic dissection | Experimental | Not described Receives: Other: MRI with 4D flow imaging; Biological: blood sampling |
| Residual type B aortic dissection following surgery for type A aortic dissection | Experimental | Not described Receives: Other: MRI with 4D flow imaging; Biological: blood sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Relevance of combining biomarkers
Measured: 3 months, 1 year, 2 years, 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jan 2026
- Study start25 Nov 2025
- Primary completionNov 2031 (estimated)
- Study completionNov 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type A Aortic Dissection With Residual Type B DissectionStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire DijonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07315178
- Sponsor's protocol ID
- BOUCHOT FEDER 2024
- Acronym
- ADEPT
- Status last verified
- Dec 2025
- First submitted
- 18 Dec 2025
- Last updated
- 2 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Creation of a Digital Twin for Predicting the Progression of Patients With Chronic Thoracic Aortic Dissection
- ClinicalTrials.gov ID
- NCT07315178
- Acronym / sponsor ID
- ADEPT / BOUCHOT FEDER 2024
- Conditions
- Type A Aortic Dissection With Residual Type B Dissection, Chronic Type B Aortic Dissection
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 25 Nov 2025 (actual)
- Primary completion
- Nov 2031 (estimated)
- Study completion
- Nov 2031 (estimated)
- First posted
- 2 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aortic dissection causes a tear in the inner layers of the aorta, leading to the formation of a true and false lumen.
There are two types of dissection: type A, which affects the ascending aorta, and type B, which affects the descending aorta. Type A aortic dissection is almost always a surgical emergency and involves replacing the ascending aorta with a prosthesis. After this type of dissection, a residual dissection remains in the descending aorta, known as residual type B dissection, which becomes chronic. This requires increased monitoring by MRI or CT scan, which are currently not effective enough to predict the development of an aneurysm that could lead to aortic rupture requiring surgical intervention. Other factors such as blood flow, the forces and mechanisms regulating blood circulation, the mechanics and histology of the aorta, and blood markers could provide a more reliable prediction of the development of an aneurysm. The creation of a digital twin model incorporating all these factors should enable better patient management.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Type B aortic dissection | Experimental | Other: MRI with 4D flow imaging, Biological: blood sampling |
| Residual type B aortic dissection following surgery for type A aortic dissection | Experimental | Other: MRI with 4D flow imaging, Biological: blood sampling |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Person who has given written consent
- Age > 18 years
- Patient with type A aortic dissection with surgical indication for replacement
- Patient with chronic type B aortic dissection, monitored and managed medically, not operated on
Key exclusion criteria (11 listed)
- Persons not affiliated with or not covered by a social security scheme
- Persons subject to legal protection measures (guardianship)
- Persons subject to judicial protection measures
- Pregnant women, women in labour or breastfeeding
- Adults who are incapacitated or unable to give their consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRI with 4D flow imagingAt 3 months | Other | Residual type B aortic dissection following surgery for type A aortic dissection, Type B aortic dissection |
| blood sampling2 tubes of 10 ml blood at inclusion, at 3 months, at 12 months, at 24 months and at 36 months | Biological | Residual type B aortic dissection following surgery for type A aortic dissection, Type B aortic dissection |
Primary outcome
Relevance of combining biomarkers
Time frame: 3 months, 1 year, 2 years, 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Alain Lalande contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRI with 4D flow imaging and blood sampling in people with Type A Aortic Dissection With Residual Type B Dissection and Chronic Type B Aortic Dissection, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alain Lalande (alain.lalande@u-bourgogne.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Relevance of combining biomarkers (time frame: 3 months, 1 year, 2 years, 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026.